Choline during pregnancy: studies of child development
What different phosphatidylcholine studies and subsequent child assessments showed.
Key points
- In one trial, 750 mg choline per day as phosphatidylcholine was taken from week 18 of pregnancy to 90 days after delivery; assessed infants showed no advantage in memory, language or overall development at 10 and 12 months. This comparison does not support expecting confirmed improvements in these measures. [1] See the evidence 1 2 3
- In another trial of 9000 mg phosphatidylcholine per day from week 16 of pregnancy until delivery, parents less often reported multiple or persistent signs of social withdrawal in children, but the main analysis found no advantage over placebo for attention problems. When considering the supplement, the preliminary signal of fewer parent-reported signs of social withdrawal can be considered separately from the lack of an advantage in attention. [2] See the evidence 1 2
- In the same trial a secondary IQ test result was higher than with placebo; 103 children from families of 206 randomized pregnant participants were assessed. When considering the supplement, take into account the preliminary signal of a higher childhood IQ test result obtained in only some participants. [2] See the evidence 1
Practical guide
Check the conclusions and whether they apply to your situation.
The studies differ in products, timing and assessed child outcomes.
Key points
Why these conclusions
Two studies
In a phosphatidylcholine study, 750 mg choline per day was taken from week 18 of pregnancy to 90 days after delivery. Assessed infants showed no advantage in memory, language or overall development at 10 and 12 months. [1]
In another study, 9000 mg phosphatidylcholine per day was taken from week 16 of pregnancy until delivery. Parents less often reported multiple or persistent signs of social withdrawal; no advantage was found in the main analysis of attention. [2]
A secondary overall IQ test result was higher in the phosphatidylcholine group; data were obtained for 103 children from families of 206 randomized pregnant participants. [2]
In the United States, the AI reference for total choline intake for adults aged 19 and older is 550 mg/day for men and 425 mg/day for women; for pregnant adults aged 19 and older it is 450 mg/day, and for lactating adults aged 19 and older 550 mg/day. AI covers food and supplements together and is not a supplement dose or a diagnostic threshold for deficiency. [3]
In the United States, the tolerable upper intake level for total choline for adults aged 19 and older is 3500 mg/day from food and supplements; it is not the dose of one supplement. High total intake can cause fishy body odor, vomiting, sweating, low blood pressure and liver damage. [3]
Infant memory at 10 and 12 months showed no advantage over placebo.
| Parameter | Data |
|---|---|
| Result | Infant memory at 10 and 12 months showed no advantage over placebo. Infant short-term and episodic memory at 10 and 12 months did not differ between groups; 99 were assessed. |
| Participants | 140 pregnant participants randomized, 99 infants assessed against a background of moderate dietary choline intake (about 360 mg/day) |
| Form | phosphatidylcholine orally |
| Dose | 750 mg choline per day as phosphatidylcholine |
| Dose basis | 750 mg choline per day as phosphatidylcholine |
| Comparator | placebo, corn oil |
| Duration | From 18 weeks of pregnancy to 90 days after delivery; children assessed at 10 and 12 months |
| Confidence | 1/4: Precision: small sample, losses or wide interval; Consistency: no substantial grounds for downgrading found.; Applicability to the specified group: indirect applicability to the general population, form or clinical outcome; Possible publication bias: no substantial grounds for downgrading found.; Study methods: study method and possible bias |
| Evidence base | 1 trial |
| Sources | [1] |
Infant language development at 10 and 12 months showed no advantage over placebo.
| Parameter | Data |
|---|---|
| Result | Infant language development at 10 and 12 months showed no advantage over placebo. Infant language development at 10 and 12 months did not differ between groups; 99 were assessed. |
| Participants | 140 pregnant participants randomized, 99 infants assessed against a background of moderate dietary choline intake (about 360 mg/day) |
| Form | phosphatidylcholine orally |
| Dose | 750 mg choline per day as phosphatidylcholine |
| Dose basis | 750 mg choline per day as phosphatidylcholine |
| Comparator | placebo, corn oil |
| Duration | From 18 weeks of pregnancy to 90 days after delivery; children assessed at 10 and 12 months |
| Confidence | 1/4: Precision: small sample, losses or wide interval; Consistency: no substantial grounds for downgrading found.; Applicability to the specified group: indirect applicability to the general population, form or clinical outcome; Possible publication bias: no substantial grounds for downgrading found.; Study methods: study method and possible bias |
| Evidence base | 1 trial |
| Sources | [1] |
Infant overall development at 10 and 12 months showed no advantage over placebo.
| Parameter | Data |
|---|---|
| Result | Infant overall development at 10 and 12 months showed no advantage over placebo. Infant overall development at 10 and 12 months did not differ between groups; 99 were assessed. |
| Participants | 140 pregnant participants randomized, 99 infants assessed against a background of moderate dietary choline intake (about 360 mg/day) |
| Form | phosphatidylcholine orally |
| Dose | 750 mg choline per day as phosphatidylcholine |
| Dose basis | 750 mg choline per day as phosphatidylcholine |
| Comparator | placebo, corn oil |
| Duration | From 18 weeks of pregnancy to 90 days after delivery; children assessed at 10 and 12 months |
| Confidence | 1/4: Precision: small sample, losses or wide interval; Consistency: no substantial grounds for downgrading found.; Applicability to the specified group: indirect applicability to the general population, form or clinical outcome; Possible publication bias: no substantial grounds for downgrading found.; Study methods: study method and possible bias |
| Evidence base | 1 trial |
| Sources | [1] |
Parents less often reported multiple or persistent signs of social withdrawal in children in the phosphatidylcholine group.
| Parameter | Data |
|---|---|
| Result | Parents less often reported multiple or persistent signs of social withdrawal in children in the phosphatidylcholine group. In 142 children the parent CBCL identified fewer multiple or persistent social withdrawal problems in the supplement group. |
| Participants | 206 pregnant participants randomized, 142 children with parent assessments |
| Form | phosphatidylcholine orally |
| Dose | 9000 mg phosphatidylcholine/day |
| Dose basis | 9000 mg phosphatidylcholine/day |
| Comparator | placebo |
| Duration | From week 16 of pregnancy until delivery; children aged 18 months–4 years |
| Confidence | 1/4: Precision: small sample, losses or wide interval; Consistency: no substantial grounds for downgrading found.; Applicability to the specified group: indirect applicability to the general population, form or clinical outcome; Possible publication bias: no substantial grounds for downgrading found.; Study methods: study method and possible bias |
| Evidence base | 1 trial |
| Sources | [2] |
The secondary overall IQ measure in children was on average 7.78 points higher than in the placebo group.
| Parameter | Data |
|---|---|
| Result | The secondary overall IQ measure in children was on average 7.78 points higher than in the placebo group. Secondary overall IQ: mean difference +7.78 points, 95% CI +1.88…+13.7; data for 103 children (54 and 49). |
| Participants | Children of some of the 206 randomized pregnant participants; secondary outcome |
| Form | phosphatidylcholine orally |
| Dose | 9000 mg phosphatidylcholine/day |
| Dose basis | 9000 mg phosphatidylcholine/day |
| Comparator | placebo |
| Duration | From week 16 of pregnancy until delivery; assessment up to age 4 |
| Confidence | 1/4: Precision: small sample, losses or wide interval; Consistency: no substantial grounds for downgrading found.; Applicability to the specified group: indirect applicability to the general population, form or clinical outcome; Possible publication bias: no substantial grounds for downgrading found.; Study methods: study method and possible bias |
| Evidence base | 1 trial |
| Sources | [2] |
No advantage was found in the main analysis of the attention scale.
| Parameter | Data |
|---|---|
| Result | No advantage was found in the main analysis of the attention scale. No significant reduction in attention problems was found in the main comparison; the exact CI is absent from the abstract. |
| Participants | 206 randomized pregnant participants, 142 children assessed by CBCL at 18 months–4 years |
| Form | Phosphatidylcholine 9000 mg/day orally |
| Dose | Phosphatidylcholine 9000 mg/day orally |
| Dose basis | Phosphatidylcholine 9000 mg/day orally |
| Comparator | Placebo |
| Duration | From week 16 until delivery, child assessed at 18 months–4 years |
| Confidence | 1/4: risk_of_bias: 64 of 206 randomized participants absent from the CBCL set; selection is possible.; inconsistency: no comparable independent series for this outcome and comparison.; indirectness: specific prenatal regimen and parent scale, without extending to a diagnosis.; imprecision: no exact CI, 142 children assessed.; publication_bias: no data for a separate downgrade. |
| Evidence base | 1 trial |
| Sources | [2] |
In the United States, the AI reference for total choline intake for adults aged 19 and older is 550 mg/day for men and 425 mg/day for women; for pregnant adults aged 19 and older it is 450 mg/day, and for lactating adults aged 19 and older 550 mg/day. AI covers food and supplements together and is not a supplement dose or a diagnostic threshold for deficiency.
In the United States, the AI reference for total choline intake for adults aged 19 and older is 550 mg/day for men and 425 mg/day for women; for pregnant adults aged 19 and older it is 450 mg/day, and for lactating adults aged 19 and older 550 mg/day. AI covers food and supplements together and is not a supplement dose or a diagnostic threshold for deficiency. [3]
In the United States, the tolerable upper intake level for total choline for adults aged 19 and older is 3500 mg/day from food and supplements; it is not the dose of one supplement. High total intake can cause fishy body odor, vomiting, sweating, low blood pressure and liver damage.
In the United States, the tolerable upper intake level for total choline for adults aged 19 and older is 3500 mg/day from food and supplements; it is not the dose of one supplement. High total intake can cause fishy body odor, vomiting, sweating, low blood pressure and liver damage. [3]
Sources
- Phosphatidylcholine supplementation in pregnant women consuming moderate-choline diets does not enhance infant cognitive function: a randomized, double-blind, placebo-controlled trial. https://pmc.ncbi.nlm.nih.gov/articles/PMC3497930/
- Prenatal Maternal Phosphatidylcholine and Children's Behavior and Cognition through 4 Years of Age: Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/42896815/
- NIH ODS Choline Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/Choline-HealthProfessional/
Methodology: Subpages evidence-led supplement pipeline v1